Vivesto Stock

Vivesto FCF/Debt

The Free Cash Flow to Debt Ratio of Vivesto (VIVE.ST) as of Aug 11, 2026 is -303.41 %. In the previous year, Free Cash Flow to Debt Ratio was -989.15 % — a change of -69.33% (higher).

FCF/Debt

-303.41 %

YoY

-69.33%

Last updated:

Free Cash Flow to Debt Ratio of Vivesto is 2026 -303.41 % . Free Cash Flow to Debt Ratio of Vivesto was 2025 -989.15 % . It decreases by -69.33% higher compared to the previous year.
Access this data via the Eulerpool API

Vivesto Stock analysis

What does Vivesto do? Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden. Vivesto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vivesto stock

Free Cash Flow to Debt Ratio of Vivesto is -303.41 % in 2026.

Free Cash Flow to Debt Ratio of Vivesto changed from -989.15 % to -303.41 %, representing a -69.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Vivesto since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Vivesto with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Vivesto

All Key Metrics — Vivesto